Molecular signatures of intrahepatic cholangiocarcinoma: role in targeted therapy selection

被引：0

作者：

Glushko, Tetiana ^{[1
]}

Costello, James ^{[1
]}

Chima, Ranjit ^{[1
]}

McGettigan, Melissa ^{[1
]}

Kim, Richard ^{[1
]}

Jeong, Daniel ^{[1
]}

Qayyum, Aliya ^{[1
]}

机构：

[1] H Lee Moffitt Canc Ctr & Res Inst, Dept Radiol, 2902 USF Magnolia Dr, Tampa, FL 33612 USA

来源：

EUROPEAN JOURNAL OF RADIOLOGY | 2025年 / 187卷

关键词：

BILIARY-TRACT CANCER; MUTATIONS; CHEMOTHERAPY; ARID1A; MULTICENTER; EXPRESSION; PROGNOSIS; SURVIVAL; FEATURES; PATHWAY;

D O I：

10.1016/j.ejrad.2025.112056

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Cholangiocarcinoma is a highly lethal disease with a 5-year overall survival rate of 7-20%. A minority of patients present with resectable disease, and relapse rates remain high. Emerging data from next generation sequencing analysis have identified various actionable mutations which drive the different disease courses opening door to precision medicine and targeted therapies. This review focuses on the clinical significance of genetic alterations as well as the role of systemic therapies, immunotherapy and targeted therapies for intrahepatic cholangiocarcinoma.

引用

页数：28

共 88 条

[11]

Choi WJ, 2022, ANN SURG ONCOL, V29, P4337, DOI 10.1245/s10434-022-11463-x

[12] Up-to-Date Pathologic Classification and Molecular Characteristics of Intrahepatic Cholangiocarcinoma [J].

Chung, Taek ;

Park, Young Nyun .

FRONTIERS IN MEDICINE, 2022, 9

[13] Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma [J].

Cleary, James M. ;

Rouaisnel, Betty ;

Daina, Antoine ;

Raghavan, Srivatsan ;

Roller, Lauren A. ;

Huffman, Brandon M. ;

Singh, Harshabad ;

Wen, Patrick Y. ;

Bardeesy, Nabeel ;

Zoete, Vincent ;

Wolpin, Brian M. ;

Losman, Julie-Aurore .

NPJ PRECISION ONCOLOGY, 2022, 6 (01)

[14]

Dumbrava EE, 2022, J CLIN ONCOL, V40

[15] HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target? [J].

Galdy, Salvatore ;

Lamarca, Angela ;

McNamara, Mairead G. ;

Hubner, Richard A. ;

Cella, Chiara A. ;

Fazio, Nicola ;

Valle, Juan W. .

CANCER AND METASTASIS REVIEWS, 2017, 36 (01) :141-157

[16] Mismatch repair deficiency is a rare but putative therapeutically relevant finding in non-liver fluke associated cholangiocarcinoma [J].

Goeppert, Benjamin ;

Roessler, Stephanie ;

Renner, Marcus ;

Singer, Stephan ;

Mehrabi, Arianeb ;

Vogel, Monika Nadja ;

Pathil, Anita ;

Czink, Elena ;

Koehler, Bruno ;

Springfeld, Christoph ;

Pfeiffenberger, Jan ;

Rupp, Christian ;

Weiss, Karl Heinz ;

Schirmacher, Peter ;

Doeberitz, Magnus von Knebel ;

Kloor, Matthias .

BRITISH JOURNAL OF CANCER, 2019, 120 (01) :109-114

[17] Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study [J].

Golan, Talia ;

Raitses-Gurevich, Maria ;

Kelley, Robin K. ;

Bocobo, Andrea G. ;

Borgida, Ayelet ;

Shroff, Rachna T. ;

Holter, Spring ;

Gallinger, Steven ;

Ahn, Daniel H. ;

Aderka, Dan ;

Apurva, Jain ;

Bekaii-Saab, Tanois ;

Friedman, Eitan ;

Javle, Milind .

ONCOLOGIST, 2017, 22 (07) :804-810

[18] Targeting FGFR inhibition in cholangiocarcinoma [J].

Goyal, Lipika ;

Kongpetch, Sarinya ;

Crolley, Valerie E. ;

Bridgewater, John .

CANCER TREATMENT REVIEWS, 2021, 95

[19] Prognosis and Clinicopathologic Features of Patients With Advanced Stage Isocitrate Dehydrogenase (IDH) Mutant and IDH Wild-Type Intrahepatic Cholangiocarcinoma [J].

Goyal, Lipika ;

Govindan, Aparna ;

Sheth, Rahul A. ;

Nardi, Valentina ;

Blaszkowsky, Lawrence S. ;

Faris, Jason E. ;

Clark, Jeffrey W. ;

Ryan, David P. ;

Kwak, Eunice L. ;

Allen, Jill N. ;

Murphy, Janet E. ;

Saha, Supriya K. ;

Hong, Theodore S. ;

Wo, Jennifer Y. ;

Ferrone, Cristina R. ;

Tanabe, Kenneth K. ;

Chong, Dawn Q. ;

Deshpande, Vikram ;

Borger, Darrell R. ;

Iafrate, A. John ;

Bardeesy, Nabeel ;

Zheng, Hui ;

Zhu, Andrew X. .

ONCOLOGIST, 2015, 20 (09) :1019-1027

[20] Biological Roles and Therapeutic Applications of IDH2 Mutations in Human Cancer [J].

Guo, Jinxiu ;

Zhang, Ruyue ;

Yang, Zhe ;

Duan, Zhenfeng ;

Yin, Detao ;

Zhou, Yubing .

FRONTIERS IN ONCOLOGY, 2021, 11

← 1 2 3 4 5 6 7 8 9 →